ReviewMolecular cancer therapeutics2023

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.

Joachim Albers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.